Randomized Cross-Over Study to Examine Associations Between Dialyzer Clotting, Uremic Toxin Removal, and Hemocompatibility During Post-Dilution Hemodiafiltration With Reduced Anticoagulation
Abstract
To date, it remains unclear to what extent dialyzer performance is affected by clotting, and which hemocompatibility parameters can reliably predict this phenomenon. This study investigated the relationship between dialyzer clotting, performance, and hemocompatibility in four commercially available dialyzers under conditions of intentionally reduced anticoagulation. This crossover study included 10 chronic hemodialysis patients, who were randomized over four dialyzers: FX CorAL800, FX CorDiax800, xevonta Hi20 (all polysulfone-based), and Solacea-19H (cellulose-based). Patients received a single bolus of one-quarter of their standard Low-Molecular-Weight Heparin (LMWH) dose. Dialysis efficiency was assessed from toxin clearance of urea, β2-microglobulin, and myoglobin. Fiber patency was evaluated through visual scoring and μCT imaging. Hemocompatibility markers, including platelet counts, leukocyte counts, anti-Xa activity, thrombin-antithrombin complex (TAT), beta-thromboglobulin (β-TG), and neutrophil-activating peptide (NAP-2), were also analyzed. μCT analysis showed that Solacea dialyzer demonstrated superior fiber patency compared to the other dialyzers. However, fiber blockage did not compromise dialysis performance, as all dialyzers maintained effective toxin removal. Platelet and leukocyte counts remained stable with FX CorAL and Solacea, while declines were found in FX CorDiax and xevonta. No significant correlations were found between clotting parameters and fiber…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 10 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.